Open-label phase 1b study of FOLFIRI plus cetuximab plus IMO-2055 in patients with colorectal cancer who have progressed following chemotherapy for advanced or metastatic disease

Phase Ib trial of the Toll-like receptor 9 agonist IMO-2055 in combination with 5-fluorouracil, cisplatin, and cetuximab as first-line palliative treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck

(2013) Jean-Pascal Machiels et al.   INVESTIGATIONAL NEW DRUGS

A phase III randomized study of gemcitabine and cisplatin with or without PF-3512676 (TLR9 agonist) as first-line treatment of advanced non-small-cell lung cancer

(2011) C. Manegold et al.   ANNALS OF ONCOLOGY

Toll-like Receptor 9 Agonist IMO Cooperates with Cetuximab in K-Ras Mutant Colorectal and Pancreatic Cancers

(2011) R. Rosa et al.   CLINICAL CANCER RESEARCH

Corticosteroids shift the Toll-like receptor response pattern of primary-isolated murine liver cells from an inflammatory to an anti-inflammatory state

(2011) R. Broering et al.   INTERNATIONAL IMMUNOLOGY

Randomized Phase III Trial of Paclitaxel/Carboplatin With or Without PF-3512676 (Toll-Like Receptor 9 Agonist) As First-Line Treatment for Advanced Non–Small-Cell Lung Cancer

(2011) Vera Hirsh et al.   JOURNAL OF CLINICAL ONCOLOGY

Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status

(2011) Eric Van Cutsem et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I clinical trial of CpG oligonucleotide 7909 (PF-03512676) in patients with previously treated chronic lymphocytic leukemia

(2011) Clive S. Zent et al.   LEUKEMIA & LYMPHOMA

Targeting the TLR9–MyD88 pathway in the regulation of adaptive immune responses

(2010) Xiaopei Huang et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Intracellular Toll-like Receptors

(2010) Amanda L. Blasius et al.   IMMUNITY

Randomized Phase III Study of Panitumumab With Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) Compared With FOLFIRI Alone As Second-Line Treatment in Patients With Metastatic Colorectal Cancer

(2010) Marc Peeters et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I trial of a Toll-like receptor 9 agonist, PF-3512676 (CPG 7909), in patients with treatment-refractory, cutaneous T-cell lymphoma

(2010) Youn H. Kim et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Safety and Efficacy of PF-3512676 for the Treatment of Stage IV Renal Cell Carcinoma: An Open-Label, Multicenter Phase I/II Study

(2009) John A. Thompson et al.   Clinical Genitourinary Cancer

Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer

(2009) Eric Van Cutsem et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phase 1 Evaluation of Intralesionally Injected TLR9-agonist PF-3512676 in Patients With Basal Cell Carcinoma or Metastatic Melanoma

(2008) Maja A. Hofmann et al.   JOURNAL OF IMMUNOTHERAPY